Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis
A Gessain, JC Vernant, L Maurs, F Barin, O Gout… - The Lancet, 1985 - Elsevier
A Gessain, JC Vernant, L Maurs, F Barin, O Gout, A Calender, G De Thé
The Lancet, 1985•ElsevierAbstract 10 out of 17 (59%) patients with tropical spastic paraparesis (TSP) had antibodies
to human T-lymphotropic virus-I (HTLV-I), as did 5 out of 5 TSP patients with systemic
symptoms. Only 13 out of 303 (4%) controls, made up of blood donors, medical personnel,
and other neurological patients, had such antibodies. These findings suggest either that
HTLV-I is neurotropic or that the virus or a related one contributes to the pathogenesis of
TSP.
to human T-lymphotropic virus-I (HTLV-I), as did 5 out of 5 TSP patients with systemic
symptoms. Only 13 out of 303 (4%) controls, made up of blood donors, medical personnel,
and other neurological patients, had such antibodies. These findings suggest either that
HTLV-I is neurotropic or that the virus or a related one contributes to the pathogenesis of
TSP.
Abstract
10 out of 17 (59%) patients with tropical spastic paraparesis (TSP) had antibodies to human T-lymphotropic virus-I (HTLV-I), as did 5 out of 5 TSP patients with systemic symptoms. Only 13 out of 303 (4%) controls, made up of blood donors, medical personnel, and other neurological patients, had such antibodies. These findings suggest either that HTLV-I is neurotropic or that the virus or a related one contributes to the pathogenesis of TSP.
Elsevier